I-R-PMPA CAS: 206184-49-8
Inombolo Yekhathalogi | XD93424 |
Igama Lomkhiqizo | I-R-PMPA |
I-CAS | 206184-49-8 |
Ifomu le-Molecularla | I-C9H16N5O5P |
Isisindo samangqamuzana | 305.23 |
Imininingwane Yesitoreji | I-ambient |
Ukucaciswa Komkhiqizo
Ukubukeka | Impushana emhlophe |
U-Asay | 99% iminithi |
I-R-PMPA, eyaziwa nangokuthi i-tenofovir disoproxil fumarate (TDF), umuthi ongalwa namagciwane osetshenziswa kakhulu ekwelapheni ukutheleleka ngegciwane lesandulela ngculazi (i-HIV) kanye nokutheleleka nge-hepatitis B (HBV) engapheli.Kuyi-prodrug yomlomo eguqulwa ibe isimo sayo esisebenzayo, i-tenofovir diphosphate, ngaphakathi emzimbeni.I-R-PMPA ingeyesigaba semithi ebizwa ngokuthi i-nucleotide reverse transcriptase inhibitors (NRTIs).Isebenza ngokuvimbela i-reverse transcriptase enzyme, ebalulekile ekuphindaphindeni kwe-HIV ne-HBV.Ngokuvimbela lesi sinyathelo esibalulekile ohlelweni lokuphindaphindeka kwegciwane, i-R-PMPA isiza ukwehlisa umthamo wegciwane egazini futhi ibambezele ukuqhubeka kwezifo. (inqola) uhlobo.Inikezwa kanye neminye imishanguzo yezidambisigciwane yezigaba ezahlukene zemithi ukuze kuthuthukiswe ukusebenza kahle kanye nokunciphisa ukukhula kokungazweli emishanguzweni.Uhlu lwemithi ethile ye-CART luzoncika ezintweni zesiguli ngasinye, njengesigaba sokutheleleka nge-HIV, umlando wokwelashwa wangaphambilini, nanoma yiziphi izimo zempilo ezihambisanayo.Ekwelapheni ukutheleleka kwe-HBV okungapheli, i-R-PMPA ivamise ukunikezwa njenge-monotherapy noma ihlanganiswe ne-HBV. eminye imithi elwa namagciwane.Ubude besikhathi sokwelashwa bungahluka kuye ngobukhulu begciwane kanye nendlela umuntu asabela ngayo emuthini. Umthamo we-R-PMPA uzonqunywa uchwepheshe wezokunakekelwa kwempilo ngokusekelwe ezicini ezifana nokusebenza kwezinso, ubudala, isisindo, kanye nokuba khona kwanoma iyiphi enye indlela. ezinye izimo zezempilo.Kubalulekile ukulandela imiyalelo yokudosa enqunyiwe futhi ungalungisi umthamo ngaphandle kokuthintana nomhlinzeki wezempilo.I-R-PMPA ngokuvamile ibekezelelwa kahle, kodwa njenganoma yimuphi umuthi, ingabangela imiphumela emibi.Imiphumela emibi evamile ihlanganisa isicanucanu, ukuhlanza, isifo sohudo, kanye nekhanda elibuhlungu.Kwezinye izimo, i-R-PMPA ingabangela imiphumela emibi kakhulu, njengokungasebenzi kahle kwezinso noma ukulahlekelwa ukuminyana kwamaminerali.Ukuqapha njalo ukusebenza kwezinso kanye nempilo yamathambo kuyanconywa ngesikhathi sokwelashwa.Kubalulekile ukuthatha i-R-PMPA njengoba kuyalelwe futhi uhambisane nemithi yokwelapha njalo.Ukweqiwa kwemithamo noma ukuyeka ukwelashwa ngaphambi kwesikhathi kungaholela ekuthuthukisweni kokungazweli emishanguzweni kanye nokuncipha kokuphumelela kokwelashwa.Kafushane, i-R-PMPA (tenofovir disoproxil fumarate) umuthi ovimbela amagciwane osetshenziswa ekwelapheni ukutheleleka nge-HIV kanye nokutheleleka nge-HBV okungapheli.Isebenza ngokuvimbela inqubo yokuphindaphindeka kwegciwane futhi ivamise ukusetshenziswa njengengxenye yokwelapha okuyinhlanganisela ye-HIV.Ukuqapha ngokucophelela kanye nokubambelela ekwelashweni kubalulekile ukuze kube nemiphumela emihle.Ukubonisana nochwepheshe bezokunakekelwa kwempilo kubalulekile ukuze kutholwe uhlelo olufanele lokwelapha kanye nokulawula noma yimiphi imiphumela emibi engase ibe khona.